Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Vericel's total debt was $13.18M at Sep 30, 2018. For fiscal 2017 it was $16.89M, up 81.2% from the year before. The highest annual figure on record is $16.89M in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $16.89M | +81.2% |
| FY2016 | Dec 31, 2016 | $9.32M | +13023.9% |
| FY2015 | Dec 31, 2015 | $71.00K | -34.9% |
| FY2014 | Dec 31, 2014 | $109.00K | +808.3% |
| FY2013 | Dec 31, 2013 | $12.00K | -70.0% |
| FY2012 | Dec 31, 2012 | $40.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2018 | Sep 30, 2018 | $13.18M | +78.1% |
| Q2 FY2018 | Jun 30, 2018 | $14.42M | +79.3% |
| Q1 FY2018 | Mar 31, 2018 | $15.65M | +80.3% |
| Q4 FY2017 | Dec 31, 2017 | $16.89M | +81.2% |
| Q3 FY2017 | Sep 30, 2017 | $7.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.04M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.32M | – |
See a number that looks wrong?